New drug axatilimab tested for Hard-to-Treat Graft-Versus-Host disease in china
NCT ID NCT06843408
First seen Nov 01, 2025 · Last updated Jun 22, 2026 · Updated 36 times
Summary
This study tests a drug called axatilimab in 30 Chinese patients with chronic graft-versus-host disease (cGVHD) that has come back or not improved after standard treatment. cGVHD is a complication of bone marrow or stem cell transplants where donor cells attack the patient's body. The trial aims to see if axatilimab is safe and can help control the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC GRAFT VERSUS HOST DISEASE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Institute of Hematology, Chinese Academy of Medical Sciences
RECRUITINGTianjin, 301617, China
-
Nanfang Hospital of Southern Medical University
RECRUITINGGuangzhou, 510515, China
-
Peking University People'S Hospital
RECRUITINGBeijing, 101149, China
-
Shanghai Children'S Medical Center
RECRUITINGShanghai, 200127, China
-
The First Affiliated Hospital, Zhejiang University School of Medicine
RECRUITINGHangzhou, 310024, China
-
The Second Affiliated Hospital, Army Medical University (Xinqiao Hospital)
RECRUITINGChongoing, 400037, China
-
Union Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology
RECRUITINGWuhan, 430022, China
-
West China Hospital of Sichuan University
RECRUITINGChengdu, 610041, China
-
Zhujiang Hospital of Southern Medical University
RECRUITINGGuangzhou, 510280, China
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
axatilimab
What this could lead to
If successful, this could provide a new treatment option for Chinese patients with chronic graft-versus-host disease that hasn't responded to other therapies.
What could go wrong
This is an early-phase trial with only 30 participants, so results may not apply broadly. Side effects are possible, and the drug may not work for everyone.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.